<b>Patients/Methods:</b> We prospectively measured several PBIMs in a PD-L1 high (TPS ≥ 50%) NSCLC cohort of patients treated with first-line pembrolizumab monotherapy. Here, CD274 is linked to non-small cell lung carcinoma.